Submission deadline: 9 Nov 2018
The PLOS Medicine editors are excited to announce this special issue, to be published in spring of 2019, guest edited by Dr Claudia Denkinger, Head of TB at FIND, Dr Richard Chaisson, director of the Johns Hopkins University Center for Tuberculosis Research, and Dr Mark Hatherill, Director of the South African Tuberculosis Vaccine Initiative. Alongside research articles, the special issue will include commissioned Perspectives by leaders in the field.
For the special issue, PLOS Medicine invites high-quality research studies with the potential to inform clinical practice or open new avenues of clinical research, with a focus on:
- Discovery and validation of novel biomarkers (including prognostic markers and predictors of response to treatment) as well as diagnostic technologies to improve case detection (thereby reaching the “missing millions”) and to rapidly inform therapy of drug-resistant infections.
- Development of new treatments for tuberculosis disease and infection, including clinical trials, clinically applicable pharmacokinetic and drug-drug interaction studies, and clinically relevant translational research evaluating novel drugs and drug combinations.
- Testing of vaccines developed for the prevention of tuberculosis infection, prevention of tuberculosis disease, or as therapeutic vaccines for prevention of recurrence after treatment.
- Implementation studies testing new strategies to find and treat tuberculosis disease and infection and to enhance adherence to therapy.
Find out more and how to submit a manuscript here.
